51ÁÔÆæ

Pharmaceutical companies operating in global markets must understand how international pharmacopoeias influence product quality, testing requirements, and regulatory compliance. In this Ask the Expert discussion, Susan J. Schniepp of 51ÁÔÆæ and Siegfried Schmitt of Parexel clarify the differences between mandatory pharmacopoeial requirements and general recommendations, helping manufacturers better understand where flexibility exists and what regulators expect.

Ìý

The experts explain that pharmacopoeial monographs, which establish product specifications and test procedures, are recognized by regulators under GMP requirements. However, general information chapters are generally considered advisory rather than mandatory. Companies may use alternative approaches, but they must document and justify how those approaches achieve GMP compliance. Simply stating that a recognized standard or guideline was followed is not sufficient without supporting documentation, such as validation plans and evidence of implementation.

The discussion also emphasizes the importance of verifying compendial test methods within individual laboratory environments. Differences in equipment, instrumentation, and operating conditions can affect method performance, making local verification essential. Additionally, companies operating internationally should be aware that some regulatory authorities may require access to original-language pharmacopoeias and personnel capable of interpreting them. Ultimately, successful global compliance requires a clear understanding of applicable requirements, scientifically justified decisions, appropriate method verification, and thorough documentation.

Read the full article: